advertisement
Abstract #46875 Published in IGR 13-3
Burden of disease in patients with glaucoma in China: Results from 2009 national health and wellness survey
Tang B; Annunziata K; Zhong Z; Dong P; Xuan JValue in Health 2010; 13: 562-563
OBJECTIVES: To assess comorbidity, quality of life (QOL), work/productivity loss, and medical resource utilization in patients suffer from glaucoma. METHODS: Patients' self-reported data were collected from 2009 National Health and Wellness Survey (NHWS). Survey samples represented major urban areas in China. QOL was measured by the physical component score (PCS) and mental component score (MCS) of the Short Form-12 (SF-12) (mean score of 50 for general population). Loss of work/ productivity was measured by the validated Work Productivity and Activity Impairment (WPAI) instrument. Medical resource utilization (MRU) was measured by health-care provider, emergency room (ER) visits and hospitalization in the past 6 months. Comparisons were made between respondents who were diagnosed glaucoma versus respondents without glaucoma (non-glaucoma group). Since glaucoma typically affects adult population, respondents with age 35 and above were included in the analysis. RESULTS: Of the 7949 survey respondents with age 35 and above, 85 (1.07%) respondents were diagnosed glaucoma. The average age in glaucoma group was 62.9 years and 43.3% were female compared to 51.9 years old with 49.3% female in non-glaucoma group. Glaucoma group reported more comorbidities, lower mean scores of PCS (39.1 vs. 47.1) and MCS (41.8 vs. 46.9), more patients visited healthcare providers (84.7% vs. 56.6%), ER (35.0% vs. 18.3%) and hospitalization (20.6% vs. 8.5%) in the past 6 months compared to non-glaucoma group. Also, glaucoma group reported 39.5% work/productivity loss (absenteeism and presenteeism) and 42.1% impairment in daily activity compared to 21.8% and 23.3% in non-glaucoma group. All comparisons in QOL, MRU, and work/productivity loss between two groups were statistically significant at P < 0.05. CONCLUSIONS: From the China NHWS results, glaucoma patients suffer from impairment in quality of life, work/ productivity loss, more comorbidities and use of medical services. The findings indicate there is still an unmet medical need in glaucoma patients in China.
B. Tang. Pfizer, New York, United States.
Classification:
14 Costing studies; pharmacoeconomics
